Data / Drug companies / Lonza Biologics, Inc.
Lonza Biologics, Inc.: 24 products in the FDA NDC directory, labeler code 67643
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
Lonza Biologics, Inc. (labeler code 67643) lists 24 products in the FDA National Drug Code Directory. By type: 24 drugs for further processing. Its main marketing category is drugs for further processing. The newest product started marketing on April 17, 2026.
The request: Watch Lonza Biologics, Inc. (FDA labeler code 67643): each new product listing and each discontinued product. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 67643
- Products in commercial distribution
- 24
- Packages
- 32
- Finished drugs by generic name
- 0
- Prescription products
- 0
- Over the counter products
- 0
- Started marketing in the last 12 months
- 2
- Earliest marketing start
- November 26, 1997
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| Drugs for further processing | 24 | 100% |
Products by type
| Type | Products | Share |
|---|---|---|
| Drugs for further processing | 24 | 100% |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Liquid | 23 | 95.8% |
| Suspension | 1 | 4.2% |
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| Burosumab | 67643-0036 | Liquid | Drugs for further processing | April 17, 2026 |
| Ocrelizumab | 67643-7001 | Liquid | Drugs for further processing | April 16, 2026 |
| Mepolizumab drug substance | 67643-0035 | Liquid | Drugs for further processing | June 27, 2025 |
| Maby | 67643-0033 | Liquid | Drugs for further processing | June 9, 2025 |
| Efgartigimod drug substance | 67643-0031 | Liquid | Drugs for further processing | October 3, 2024 |
| Infliximab 40.0 mg/ml drug substance | 67643-0012 | Liquid | Drugs for further processing | August 21, 2024 |
| Tafasitamab | 67643-0029 | Liquid | Drugs for further processing | July 12, 2024 |
| Vedolizumab sc | 67643-0034 | Liquid | Drugs for further processing | April 1, 2024 |
| Fremanezumab | 67643-0028 | Liquid | Drugs for further processing | September 28, 2023 |
| Isatuximab | 67643-0032 | Liquid | Drugs for further processing | November 21, 2022 |
| Lisocabtagene maraleucel lentivirus vector | 67643-5008 | Suspension | Drugs for further processing | February 5, 2021 |
| Eftrenonacog alfa | 67643-0024 | Liquid | Drugs for further processing | December 22, 2020 |
| Vedolizumab iv | 67643-0023 | Liquid | Drugs for further processing | April 6, 2018 |
| Ocrelizumab | 67643-7000 | Liquid | Drugs for further processing | March 28, 2017 |
| Obiltoxaximab | 67643-0018 | Liquid | Drugs for further processing | March 18, 2016 |
| Asfotase alfa | 67643-0017 | Liquid | Drugs for further processing | October 23, 2015 |
| Pertuzumab | 67643-7004 | Liquid | Drugs for further processing | June 8, 2012 |
| Pertuzumab | 67643-7003 | Liquid | Drugs for further processing | June 8, 2012 |
| Pertuzumab | 67643-7002 | Liquid | Drugs for further processing | June 8, 2012 |
| Ofatumumab | 67643-0016 | Liquid | Drugs for further processing | April 1, 2011 |
| Tocilizumab | 67643-7008 | Liquid | Drugs for further processing | January 8, 2010 |
| Tocilizumab | 67643-7007 | Liquid | Drugs for further processing | January 8, 2010 |
| Rituximab | 67643-7006 | Liquid | Drugs for further processing | November 26, 1997 |
| Rituximab | 67643-7005 | Liquid | Drugs for further processing | November 26, 1997 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.